Envista Holdings Corporation today announced it has entered into a definitive agreement to acquire Osteogenics Biomedical Inc, Allotech LLC and OBI Biologics, Inc (together “Osteogenics”). The transaction is subject to customary regulatory approvals and expected to close in the Third Quarter.

Osteogenics is a leader in the development of innovative regenerative solutions for periodontists, oral & maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world.  Primarily sold under the CytoplastTM brand name, Osteogenics offers a complete line of bone grafting products.  Bone grafting and regenerative therapies are often a critical step in implant based tooth replacements.  By improving bone stability, regenerative solutions support better clinical outcomes for more patients.

“Increasing our capabilities in regenerative solutions is consistent with our intention to digitize, personalize, and democratize oral care.  Osteogenics is a recognized pioneer in membrane technologies used in dental bone grafting procedures.  They are a trusted brand and have a proven track record of growth.  We are excited to welcome the Osteogenics team to Envista.”

Envista’s CEO Amir Aghdaei

Next Post

Unlocking the potential of healthcare data in research

At the height of the COVID-19 pandemic, these capabilities were put to the test, being used to compare hospital caseloads to research activity in real-time and enabling COVID-19 clinical trials to rapidly recruit participants across the UK. Having demonstrated the possibilities when multiple agencies work together towards the same single […]